Amid re­peat­ed stum­bles, Pfiz­er and Eli Lil­ly tout their an­ti-NGF pain drug tanezum­ab — but ques­tions linger

Pfiz­er and Eli Lil­ly have start­ed to make their late-stage case for tanezum­ab, out­lin­ing some pos­i­tive re­sults on pain but rais­ing some se­ri­ous is­sues about just how ef­fec­tive this low-dose pain drug could be.

Ac­cord­ing to their re­searchers, the drug, an­gling for the non-opi­oid mar­ket the feds want to pro­mote, hit sta­tis­ti­cal sig­nif­i­cance against a place­bo — scor­ing on 3 out of 3 pri­ma­ry end­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER